Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

WH Smith 'well-positioned' for future growth

(Sharecast News) - Retailer WH Smith said on Wednesday that it was "well-positioned for future growth" as a pure-play travel retailer after the segment turned in a strong H1 performance. WH Smith said total group revenues were up 3% at £951.0m, with total travel revenues improving 6% year-on-year at £712.0m. Travel revenues rose 7% in the UK, 5% in North America and 15% in the rest of the world.

Headline group pre-tax profits slipped from £46.0m to £45.0m as a £7.0m drop in high street trading profits to £15.0m offset a 12% jump in total travel trading profits to £56.0m.

WH Smith, which agreed to the sale of its High Street business on 28 March, also declared an interim dividend of 11.3p per share, reflecting "strong trading and cash generation" combined with its confidence in its future growth prospects.

Chief executive Carl Cowling said: "The group has had a good first half with consistent like-for-like growth across all our travel businesses, and we are well-positioned for the peak summer trading period.

"The second half of the financial year has started well, and we remain on track to deliver full-year results in line with market expectations. We are mindful of the increased level of geopolitical and economic uncertainty, however, given the resilient nature of our business, we are well-positioned to benefit from the growth opportunities in global travel retail."

As of 0850 BST, WH Smith shares were down 1.14% at 939.64p.

Reporting by Iain Gilbert at Sharescast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.